Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
Kymera Gets FDA Clearance for Phase 1 Testing of KT-621
The FDA Clears Kymera Therapeutics' Investigational New Drug Application For KT-621, The Company Expects To Initiate Dosing In A Phase 1 Trial In Healthy Volunteers In October 2024 And To Report Data In The First Half Of 2025
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
The Analyst Landscape: 7 Takes On Kymera Therapeutics
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $56
Oppenheimer Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $60
Kymera Therapeutics Says Its Potential IND KT-621 Reduced Inflammation in Preclinical Models
Kymera Therapeutics Announced The Presentation Of Preclinical Data For KT-621 For TH2-driven Allergic And Atopic Diseases, The Company Intends To Initiate Phase 1 Trial In 2H 2024, With Data Anticipated In 1H 2025
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Leerink Partners Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $60
Leerink Partners analyst Faisal Khurshid initiates coverage on $Kymera Therapeutics(KYMR.US)$ with a buy rating, and sets the target price at $60.According to TipRanks data, the analyst has a
Express News | Kymera Therapeutics Inc : Leerink Partners Assumes Coverage With Outperform Rating; Target Price $60
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics Shares Rise After Wolfe Research Upgrade
This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday